- Home
- BNTC
as of 01-20-2026 3:54pm EST
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 405.7M | IPO Year: | N/A |
| Target Price: | $27.67 | AVG Volume (30 days): | 171.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.70 - $17.15 | Next Earning Date: | 02-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BNTC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Benitec Biopharma Inc. (BNTC)
Director, 10% Owner
Avg Cost/Share
$13.44
Shares
77,387
Total Value
$1,040,081.28
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$13.10
Shares
16,836
Total Value
$220,551.60
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$12.85
Shares
50,000
Total Value
$642,500.00
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$12.08
Shares
19,542
Total Value
$236,067.36
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$11.48
Shares
16,384
Total Value
$188,088.32
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$11.24
Shares
10,215
Total Value
$114,816.60
Owned After
1,848,156
Director, 10% Owner
Avg Cost/Share
$13.50
Shares
1,481,481
Total Value
$19,999,993.50
Owned After
1,848,156
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 29, 2025 | Buy | $13.44 | 77,387 | $1,040,081.28 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 26, 2025 | Buy | $13.10 | 16,836 | $220,551.60 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 23, 2025 | Buy | $12.85 | 50,000 | $642,500.00 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 22, 2025 | Buy | $12.08 | 19,542 | $236,067.36 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 19, 2025 | Buy | $11.48 | 16,384 | $188,088.32 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 18, 2025 | Buy | $11.24 | 10,215 | $114,816.60 | 1,848,156 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Nov 7, 2025 | Buy | $13.50 | 1,481,481 | $19,999,993.50 | 1,848,156 |
Compare BNTC vs Leading Stocks
See how BNTC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.